DK2295417T3 - Nye mellemprodukter, som kan anvendes til fremstilling af alpha-(n-sulfonamid)acetamidforbindelse - Google Patents

Nye mellemprodukter, som kan anvendes til fremstilling af alpha-(n-sulfonamid)acetamidforbindelse

Info

Publication number
DK2295417T3
DK2295417T3 DK10190591.7T DK10190591T DK2295417T3 DK 2295417 T3 DK2295417 T3 DK 2295417T3 DK 10190591 T DK10190591 T DK 10190591T DK 2295417 T3 DK2295417 T3 DK 2295417T3
Authority
DK
Denmark
Prior art keywords
sulfonamide
novel intermediates
acetamide compound
prepare alpha
alpha
Prior art date
Application number
DK10190591.7T
Other languages
Danish (da)
English (en)
Inventor
John E Starrett Jr
Kevin W Gillman
Richard E Olson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2295417(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK2295417T3 publication Critical patent/DK2295417T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK10190591.7T 2007-10-31 2008-10-14 Nye mellemprodukter, som kan anvendes til fremstilling af alpha-(n-sulfonamid)acetamidforbindelse DK2295417T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31
EP08843687A EP2205575B1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Publications (1)

Publication Number Publication Date
DK2295417T3 true DK2295417T3 (da) 2012-10-15

Family

ID=40193955

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10190591.7T DK2295417T3 (da) 2007-10-31 2008-10-14 Nye mellemprodukter, som kan anvendes til fremstilling af alpha-(n-sulfonamid)acetamidforbindelse
DK08843687.8T DK2205575T3 (da) 2007-10-31 2008-10-14 Ny alpha-(n-sulfonamid)acetamid-forbindelse som inhibitor af betaamyloidpeptid-produktion

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08843687.8T DK2205575T3 (da) 2007-10-31 2008-10-14 Ny alpha-(n-sulfonamid)acetamid-forbindelse som inhibitor af betaamyloidpeptid-produktion

Country Status (28)

Country Link
US (2) US8084477B2 (https=)
EP (3) EP2205575B1 (https=)
JP (1) JP5460605B2 (https=)
KR (1) KR20100075575A (https=)
CN (2) CN102718689A (https=)
AR (1) AR069135A1 (https=)
AT (1) ATE502022T1 (https=)
AU (1) AU2008319122A1 (https=)
BR (1) BRPI0818837A2 (https=)
CA (1) CA2704360A1 (https=)
CL (1) CL2008003271A1 (https=)
CO (1) CO6270332A2 (https=)
CY (2) CY1112337T1 (https=)
DE (1) DE602008005636D1 (https=)
DK (2) DK2295417T3 (https=)
EA (2) EA201171439A1 (https=)
ES (2) ES2390042T3 (https=)
HR (2) HRP20110219T1 (https=)
IL (1) IL205406A0 (https=)
MX (1) MX2010004319A (https=)
NZ (1) NZ584545A (https=)
PE (1) PE20091394A1 (https=)
PL (2) PL2205575T3 (https=)
PT (2) PT2205575E (https=)
SG (2) SG174043A1 (https=)
SI (2) SI2205575T1 (https=)
TW (1) TW200927099A (https=)
WO (1) WO2009058552A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471099C (en) 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
CN102438622A (zh) * 2009-03-19 2012-05-02 百时美施贵宝公司 作为β淀粉样肽产生抑制剂的新颖α-(N-磺酰氨基)乙酰胺化合物
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
AU2011225122B8 (en) 2010-03-12 2013-12-12 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
EP2643299B1 (en) 2010-11-22 2016-06-22 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
CN104797569A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 取代的1,5-苯并二氮杂*酮化合物
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
WO2014047392A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
WO2018111926A2 (en) 2016-12-16 2018-06-21 Inception 3, Inc. Methods of treating cochlear synaptopathy
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
KR102870868B1 (ko) 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
CN119679936A (zh) 2019-06-24 2025-03-25 诺华股份有限公司 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
SK282833B6 (sk) * 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
JP2000515153A (ja) 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
AU766192B2 (en) 1999-01-27 2003-10-09 Wyeth Holdings Corporation Acetylenic sulfonamide thiol tace inhibitors
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
IL159140A0 (en) * 2001-12-14 2004-06-01 Raytheon Co Precisely aligned lens structure and a method for its fabrication
CA2471099C (en) 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
CN1653064A (zh) * 2002-02-28 2005-08-10 阿斯特拉曾尼卡有限公司 噁唑烷酮衍生物、其制备方法以及包含它们的药用组合物
ES2286345T3 (es) * 2003-03-20 2007-12-01 Santhera Pharmaceuticals (Schweiz) Ag Derivados de piperidina y piperazina substituidos como moduladores del receptor de melanocortina-4.
KR20060002908A (ko) * 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
US7144894B2 (en) * 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
EP1984321A1 (en) * 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
AR059517A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
TW200927099A (en) 2009-07-01
CY1112337T1 (el) 2015-12-09
US8350084B2 (en) 2013-01-08
AU2008319122A1 (en) 2009-05-07
HRP20110219T1 (hr) 2011-04-30
MX2010004319A (es) 2010-04-30
JP5460605B2 (ja) 2014-04-02
PE20091394A1 (es) 2009-09-25
KR20100075575A (ko) 2010-07-02
EP2205575B1 (en) 2011-03-16
WO2009058552A1 (en) 2009-05-07
CO6270332A2 (es) 2011-04-20
CN101910141B (zh) 2012-12-19
BRPI0818837A2 (pt) 2015-04-22
SI2205575T1 (sl) 2011-07-29
ATE502022T1 (de) 2011-04-15
US8084477B2 (en) 2011-12-27
JP2011502153A (ja) 2011-01-20
AR069135A1 (es) 2009-12-30
DK2205575T3 (da) 2011-07-11
SG174043A1 (en) 2011-09-29
PL2295417T3 (pl) 2012-11-30
DE602008005636D1 (de) 2011-04-28
CA2704360A1 (en) 2009-05-07
EP2295417B1 (en) 2012-07-04
EP2295417A1 (en) 2011-03-16
EA201000714A1 (ru) 2010-10-29
EA016447B1 (ru) 2012-05-30
HK1155161A1 (en) 2012-05-11
CN101910141A (zh) 2010-12-08
CY1113346T1 (el) 2016-06-22
CL2008003271A1 (es) 2009-07-10
EP2471769A1 (en) 2012-07-04
IL205406A0 (en) 2010-12-30
EA201171439A1 (ru) 2012-05-30
US20120088925A1 (en) 2012-04-12
NZ584545A (en) 2011-04-29
SG174044A1 (en) 2011-09-29
US20090111858A1 (en) 2009-04-30
PL2205575T3 (pl) 2011-09-30
EP2205575A1 (en) 2010-07-14
CN102718689A (zh) 2012-10-10
PT2295417E (pt) 2012-09-26
SI2295417T1 (sl) 2012-11-30
HK1141801A1 (en) 2010-11-19
HRP20120703T1 (hr) 2012-09-30
ES2390042T3 (es) 2012-11-06
PT2205575E (pt) 2011-05-23
ES2361283T3 (es) 2011-06-15

Similar Documents

Publication Publication Date Title
DK2295417T3 (da) Nye mellemprodukter, som kan anvendes til fremstilling af alpha-(n-sulfonamid)acetamidforbindelse
DK2010498T3 (da) Syntese af acylaminoalkenylenamider, der kan anvendes som substans P-antagonister
DK2086960T3 (da) Nye inhibitorer af glutaminylcyclase.
DK2315756T3 (da) 1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
DK2455374T3 (da) Fremgangsmåde til fremstillingen af forbindelser der kan anvendes som inhibitorer af SGLT
DK2310382T3 (da) Amidophenoxyindazoler, der er anvendelige som hæmmere af c-met
DK2375967T3 (da) Kamera til registrering af overfladestrukturer, såsom med henblik på dentale anvendelser.
DK2300465T3 (da) Imidazopyridinderivater som hæmmere af receptortyrosinkinaser
DK2242752T3 (da) Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2190289T3 (da) Isoxazolinforbindelser og deres anvendelse som antiparasitika
DK2094842T3 (da) Nye laccaser, sammensætninger og anvendelsesfremgangsmåder
DK2279263T3 (da) Rnase-h-baserede assays med anvendelse af modificerede rna-monomerer
DK2379532T3 (da) Forbindelser, som er egnet til hæmning af chk1
DK2061465T3 (da) Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer
DK3320912T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
DK2421537T3 (da) Pyrazolylaminopyridiner som inhibitorer af FAK
DK2180882T3 (da) Farmaceutisk faststofsammensætning af matrix-type
DK3219815T3 (da) Fremgangsmåder og sammensætninger til at fremstille squalen under anvendelse af gær
DK2449057T3 (da) Fremgangsmåde til omdannelse af lignocellulosematerialer til anvendelige kemikalier
DK2593449T3 (da) Fremgangsmåde til syntese af benzothiadiazolforbindelse
DK2091945T3 (da) Nye inhibitorer af glutaminylcyclase
BR112012002155A2 (pt) composição de solvente
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2120936T3 (da) Nye fremgangsmåder